L-Histidine

L-Histidine, an amino acid with potential therapeutic properties, is currently being studied in clinical trials for its effects on Alzheimer’s Disease and fatigue in Multiple Sclerosis. These trials aim to investigate how L-Histidine supplementation might improve cognitive function and reduce fatigue symptoms in patients with these neurological conditions.

Table of Contents

What is L-Histidine?

L-Histidine is an amino acid that is being studied as a potential treatment for various medical conditions. It is also known by its synonym, Histamine[1]. Researchers are particularly interested in its effects on brain function and its potential to alleviate symptoms in neurological disorders.

L-Histidine for Alzheimer’s Disease

One of the most promising areas of research for L-Histidine is in the treatment of Alzheimer’s disease. Alzheimer’s is a progressive brain disorder that affects memory, thinking skills, and the ability to carry out simple tasks[2]. Researchers are investigating whether L-Histidine supplementation can help improve cognitive function in people with this condition.

The potential benefits of L-Histidine for Alzheimer’s patients include:

  • Increased blood flow to the brain: This could help deliver more oxygen and nutrients to brain cells.
  • Promotion of neurogenesis: This is the process of creating new brain cells, which could potentially replace damaged ones.
  • Stimulation of angiogenesis: This involves the formation of new blood vessels, which could improve overall brain health.
  • Activation of histaminergic neural pathways: These pathways are involved in various brain functions, including alertness and memory.
  • Enhanced autophagy of beta-amyloid protein: This could help clear out the harmful protein buildup that is characteristic of Alzheimer’s disease.

L-Histidine for Multiple Sclerosis Fatigue

Another area of research for L-Histidine is in treating fatigue associated with Multiple Sclerosis (MS). MS is a condition that affects the central nervous system, and fatigue is one of its most common and debilitating symptoms[1]. Researchers are exploring whether L-Histidine supplementation can help reduce this fatigue and improve quality of life for MS patients.

How L-Histidine Works

L-Histidine is believed to work by increasing levels of certain compounds in the brain, including:

  • Anserine: A compound that may have antioxidant properties.
  • Carnosine: Another compound with potential antioxidant effects.
  • Histamine: A neurotransmitter involved in various brain functions.

These increased levels are thought to contribute to improved cognitive function and reduced fatigue[2].

Dosage and Administration

The dosage and administration of L-Histidine can vary depending on the specific condition being treated:

  • For Alzheimer’s disease: Patients may start with 2 grams of L-Histidine powder or capsules taken before noon. The dose may be gradually increased every two weeks up to 4, 6, or 8 grams per day as tolerated, for up to 3 months[2].
  • For MS-related fatigue: Patients may take 1000 mg capsules twice daily (morning and evening)[1].

It’s important to note that L-Histidine should only be taken under medical supervision. In some studies, it is given along with other supplements or medications, such as a multivitamin containing zinc and folic acid for Alzheimer’s patients, or Lodosyn for MS patients[1][2].

Potential Side Effects

As with any medication or supplement, L-Histidine may cause side effects. In the ongoing studies, researchers are carefully monitoring for any adverse events[1]. It’s crucial for patients to report any unusual symptoms to their healthcare provider promptly.

Remember, L-Histidine is still being researched, and its full effects and potential benefits are not yet fully understood. If you’re interested in L-Histidine as a potential treatment, it’s essential to discuss this with your doctor and not to start any new treatments without medical supervision.

Aspect Alzheimer’s Disease Trial Multiple Sclerosis Trial
Purpose Improve cognition Reduce fatigue
L-Histidine Dosage 2g to 8g per day, titrated 1000mg twice daily
Duration Up to 3 months 2 weeks per treatment period
Primary Outcome Change in Clinical Dementia Rating Incidence of Adverse Events
Secondary Outcomes Histidine and histamine blood levels Fatigue scales (FSS, MFIS, VAS) and quality of life (MSQOL)
Study Design Randomized, placebo-controlled Double-blind randomized cross-over

Ongoing Clinical Trials on L-Histidine

  • Study on Ketoanalogue Supplementation for Muscle Protection in Patients with Stage 4 and 5 Chronic Kidney Disease on a Low Protein Diet

    Recruiting

    1 1 1 1
    Investigated diseases:
    France
  • Study on the Effectiveness of Ketoanalogues in Preventing Muscle Loss in Patients with Nephrotic Syndrome

    Recruiting

    1 1 1 1
    Investigated diseases:
    Poland
  • Study comparing Custodiol-N and Custodiol organ preservation solutions for heart transplantation in children

    Recruiting

    1 1 1
    Investigated diseases:
    Germany
  • Study on Organ Preservation in Kidney, Liver, and Pancreas Transplants Using Custodiol-N Solution Compared to a Drug Combination for Transplant Patients

    Recruiting

    1 1 1 1
    Investigated diseases:
    Austria
  • Ketosteril Added to Usual Nutrition for Patients Starting Incremental Haemodialysis with Incremental Haemodialysis

    Not yet recruiting

    1 1 1
    Investigated diseases:
    France
  • Study on the Impact of Acetylcysteine and Drug Combination on Kidney Function in Living Donor Kidney Transplant Patients

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Spain
  • Study Comparing Custodiol-N and Custodiol for Heart Surgery in Children with Congenital Heart Defects

    Not yet recruiting

    1 1 1
    Germany
  • Study on the Effects of Custodiol and Buckberg Cardioplegia in Patients Undergoing Major Heart Surgery with Prolonged Aortic Clamping

    Not yet recruiting

    1 1 1 1
    Spain

Glossary

  • L-Histidine: An amino acid being studied for its potential therapeutic effects in neurological conditions, believed to increase levels of certain brain chemicals that may improve cognition and reduce fatigue.
  • Alzheimer's Disease: A progressive brain disorder that slowly destroys memory and thinking skills, and eventually the ability to carry out simple tasks.
  • Multiple Sclerosis (MS): A disease of the central nervous system that disrupts the flow of information within the brain and between the brain and body.
  • Clinical Dementia Rating-Sum of Boxes (CDR-SB): A scale used to measure cognitive function in Alzheimer's Disease, ranging from 0 to 18, with higher scores indicating greater impairment.
  • Fatigue Severity Scale (FSS): A 9-item questionnaire used to measure how fatigue interferes with certain activities, scored on a 7-point scale.
  • Modified Fatigue Impact Scale (MFIS): A scale used to measure fatigue, with scores ranging from 0 to 84, where 0 is the best possible score and 84 is the worst.
  • Visual Analog Scale (VAS): A measurement tool that allows patients to rate their health on a 20 cm vertical scale, with higher numbers indicating better outcomes.
  • Multiple Sclerosis Quality of Life (MSQOL): A scale used to measure quality of life in MS patients, with scores ranging from 0 to 100, where higher scores indicate better quality of life.
  • Placebo: A substance with no active therapeutic effect, used as a control in clinical trials to test the effectiveness of another substance.
  • Double-blind randomized cross-over: A study design where neither the participants nor the researchers know who is receiving the treatment or placebo, and participants receive both treatments at different times.

References

  1. https://clinicaltrials.gov/study/NCT04764383
  2. https://clinicaltrials.gov/study/NCT06169826